// App-Quantinova.ai

Sa1241 : Pharmacology of Etrolizumab in a Phase 2 Study in Moderate-to-Severely Active Ulcerative Colitis

Researchers

Presenter

  • Franklin Fuh

Principal Investigators

  • Houston Gilbert

  • Diana Luca

  • Jackson G. Egen

  • Severine Vermeire

  • John C. Mansfield

  • Christopher A. Lamb

  • Brian G. Feagan

  • Julian Panes

  • Daniel C. Baumgart

  • Stefan Schreiber

  • Xiaohui Wei

  • Iris Dotan

  • William Sandborn

  • Paul J. Rutgeerts

  • Timothy Lu

  • Sharon -Byrne

  • Marna Williams

  • Mary E. Keir

  • Gaik W. Tew

  • Jeffrey Eastham-Anderson

  • Lauri Diehl

  • Azucena Salas

  • Gert De Hertogh

  • Steven Francom

Medical Centers

  • University of Newcastle, Newcastle, United Kingdom,

  • University of California, San Diego, La Jolla, CA

  • Christian-Albrechts-University, Kiel, Germany

  • University of Western Ontario, London, ON, Canada

  • Hospital Clinic Barcelona, Barcelona, Spain

  • Tel Aviv Sourasky Medical Center and Sakler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

  • University of Leuven, KUL, Leuven, Belgium

  • Humboldt University of Berlin, Berlin, Germany

Locations

  • Canada

  • Germany

  • Spain

  • United Kingdom

  • United States

  • Israel

  • Belgium

Companies

  • F. Hoffmann-La Roche

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Ulcerative colitis

Biomarkers

  • Cadherin 1

  • Cluster of Differentiation 19

  • Cluster of Differentiation 2AP

Drug/Treatment

  • Etrolizumab

Outcome

  • N/A

Study Design

  • pharmacokinetics

  • pharmacodynamics

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved